Insilico Biotechnology AG offers a suite of Digital Twins that delivers high quality predictions for accelerating product time to market.
Biopharmaceutical companies have growing drug pipelines which require ever more efficient development processes for each new product without compromising on achieving high product titers and desired quality profiles. In close alignment with customer needs Insilico Biotechnology AG has developed a modular suite of Digital Twins that cover key steps during bioprocess development. The application of these powerful predictive solutions leads to drastically reduced development timelines without a trade-off on titer or quality. Digital Twins enable the exploration of the multi-dimensional design space of cell culture processes by replacing time-consuming and costly wet-lab experiments with virtual experimentation.
The modular portfolio of Digital Twins is embedded in Insilico’s technology platform for standardized and automated data processing. The platform comprises the cellular metabolic network model, the mechanistic process model as well as machine learning technology for generating a predictive Digital Twin. The integrated Insilico Analyzer allows the identification of metabolic limitations by time-resolved analyses of intracellular fluxes based on extracellular metabolite data.
"Enabling the access to a whole ecosystem of Digital Twins supports the paradigm shift towards biopharma 4.0. We are very enthusiastic and pleased that we can support our customers in their digitalization journey with our predictive solutions." says Klaus Mauch, CEO, Insilico Biotechnology
Customers have the option of either licensing Insilico's Digital Twin solutions for in-house use or request Insilico's services for specific products within their pipeline.
We use cookies to help provide you with the best possible online experience.
By using this site, you agree that we may store and access cookies on your device.
You can find out more and set your own preferences here.
